TickerRisk
Learn Pricing Open Scanner

AMGEN INC (AMGN) Options Risk Score

Real-time risk analysis for AMGN options traders — updated every 30 minutes.

64
MEDIUM Risk
62.5
IV Rank
34.7%
IV %
2026-08-04
Next Earnings
Biological Products, (No Diagnostic Substances)
Sector

Data last updated: 2026-07-23

Run a full AMGN options risk analysis

See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.


Scan AMGN Now — Free →

Is it risky to sell options on AMGEN INC (AMGN) right now?

AMGEN INC (AMGN) currently scores 64 out of 100 for options catalyst risk (MEDIUM) over a 4-week expiry window. That score is driven by 3 recent news items, 10 active legal filings and 18 clinical-trial catalysts falling inside the 4-week window. A mid-range score (45–69) means AMGN is neither clear nor obviously dangerous over this window — check which specific date is driving it before choosing a strike. The number reflects event exposure only.

AMGN shows an IV Rank of 62, putting implied volatility in the middle of its one-year range — options are moderately priced, with a current implied volatility of about 35%. IV Rank is the most useful figure for deciding whether to sell or buy premium on AMGN.

The next AMGN report is not until 2026-08-04, beyond the near-term window.

TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer